Synthesis and Turnover of beta 2-Microglobulin in Ad12-transformed Cells Defective in Assembly and Transport of Class I Major Histocompatibility Complex Molecules*

(Received for publication, June 19, 1996)

Sigal Vinograd Mey-Tal , Chana Schechter and Rachel Ehrlich Dagger

From the Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv 64978, Israel

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgment
REFERENCES


ABSTRACT

In primary embryonal fibroblasts from transgenic mice expressing H-2 genes and a miniature swine class I transgene (PD1), transformation with the highly oncogenic Ad12 results in a reduction in peptide transporter and proteasome-associated (LMP2 and LMP7) gene expression, and suppression in transport and cell surface expression of all class I antigens. The selective suppression in transport of H-2 (but not of PD1) molecules in cells reconstituted for the expression of peptide transporter and LMP genes implied that an additional factor(s) is involved in the assembly of class I complexes. Here we show that the beta 2m, H-2Db, and H-2Kb genes are transcribed and translated in Ad12-transformed cells. However, unlike normal and E1Ad5-transformed cells, in which beta 2m is either secreted unbound or bound to class I heavy chains, in Ad12-transformed cells significant amounts of beta 2m are retained in the cell bound to the membrane, but free of class I heavy chains. This abnormal turnover of beta 2m in the Ad12-transformed cells suggests the existence of a novel beta 2m-binding molecule(s) that sequesters beta 2m, and this process may provide a mechanism by which transformation with Ad12 may subvert class I complex formation.


INTRODUCTION

MHC1 class I molecules are polymorphic, integral membrane proteins that bind a diverse group of peptides derived from endogenous antigens and display these peptides for recognition by cytotoxic T-lymphocytes (1). This mechanism enables the immune system to control infectious diseases and the growth of tumor cells (2, 3). Indeed, cells infected by a variety of viruses that interfere with cell surface expression of class I antigens, as well as tumors of various origins that demonstrate suppressed levels of class I antigens, can escape immune surveillance (4).

The biochemistry and cell biology of antigen processing and presentation by class I MHC molecules has been analyzed in detail in recent years (5, 6). It is well established that the efficient transport of class I molecules to the cell surface depends on the assembly of the heavy chain/beta 2m dimer with peptides that are usually 8-9 amino acids long. Such peptides, generated by cleavage of proteins in the cytosol, are actively transported by a heterodimeric complex, known as transporter associated with antigen presentation (TAP), into the endoplasmic reticulum (ER), where assembly with class I molecules takes place. The trimeric complex is then transported through the Golgi apparatus to the cell surface. Mutant cell lines (5, 6, 7, 8), "knockout" mice (9, 10), and tumor cells (4, 11, 12), which do not express TAP genes, are generally devoid of cell surface MHC class I molecules. Cell lines and knockout mice lacking beta 2m expression also fail to display normal cell surface class I MHC molecules (13, 14, 15). The crucial role of beta 2m is evident from data demonstrating that it stabilizes cell surface expression of class I heavy chains, facilitates the binding of purified class I molecules to antigenic peptides both on cells and plastic surfaces, and generates additional high affinity peptide-binding sites in preparations of soluble purified class I molecules (16, 17, 18, 19, 20). These data, as well as the finding that beta 2m determines the fate of class I heavy chains (21), suggest that beta 2m may play a predominant role in maintaining the class I heavy chain in a non-denatured conformation suitable for terminal folding upon binding of peptide. Such a model predicts a role for extracellular beta 2m in providing a microenvironment that supports the existence of cell surface beta 2m/heavy chain dimers capable of binding peptides. Indeed, both constitutive and peptide-induced class I surface expression can be augmented markedly, in some cases, by the presence of exogenous beta 2m (21, 22). The existence of a substantial pool of inactive heavy chains on the cell surface, which are able to bind added beta 2m at 37 °C, has been demonstrated by Rock et al. (23), implying a physiological role for exogenous beta 2m in maintaining cell surface class I heavy chains in a state suitable for subsequent binding of exogenous peptides.

Increased levels of beta 2m can be detected both in the peripheral circulation and locally, in many abnormal in vivo conditions (24, 25, 26, 27, 28). Additionally, lymphoid and hepatoma cells have been shown to produce and secrete beta 2m when stimulated with various cytokines (29, 30). If these augmented levels facilitate the accumulation of class I-bound peptides, then the regulation of beta 2m secretion may have functional consequences. Supportive of such a role are data demonstrating the strong in vivo priming of cytotoxic T-lymphocytes to class I-binding peptides if the latter are combined with beta 2m when injected into mice (31).

We have shown previously that, in primary embryonal fibroblasts from transgenic mice expressing both endogenous H-2 genes and a miniature swine class I transgene (PD1), transformation with the highly oncogenic Ad12 results in inhibition of the transport of newly synthesized class I molecules via the Golgi apparatus, a significant reduction in peptide transporter (TAP1 and TAP2) and in proteasome-associated (LMP2 and LMP7) gene expression, and in suppression of cell surface expression of all class I antigens (12, 32, 33, 34). Expression of these class I genes is either normal or up-regulated in cells transformed by the non-oncogenic virus-Ad5. Re-expression of TAP and LMP in an Ad12-transformed cell line completely reconstituted the cell surface expression and transport of PD1 and induced the transport of 20% of the H-2Db molecules, but did not affect the transport or expression of H-2Kb molecules (34). These data, as well as the fact that in Ad12-transformed cells, H-2 molecules were not recognized by conformation-independent antibodies (33, 34), raised the possibility that either the synthesis of beta 2m in these cells is defective and the class I heavy chains compete for a limited amount of beta 2m molecules (PD1 being more competitive), or that Ad12-transformed cells are deficient in a factor(s) that facilitate the assembly of beta 2m with a particular set of class I heavy chains (H-2). We now present data substantiating that beta 2m, as well as H-2Db and H-2Kb, are transcribed and translated in Ad12-transformed cells. However, the results show an abnormal turnover of beta 2m molecules and suggest the existence of a novel beta 2m-binding molecule(s) that acts to retain beta 2m in the transformed cells.


EXPERIMENTAL PROCEDURES

Cell Cultures

The Ad12-transformed (VAD12.79, VAD12.42, VAD12.20, VAD12.25, VAD12.36, VAD12.54, and VAD12.43), E1Ad5-transformed (A5O1 and A5O5), and TAP-transfected cell lines and the normal cell line M1 have been described previously (32, 33, 34). Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10% fetal calf serum, penicillin, streptomycin, gentamycin, and amphotericin B at the recommended concentrations (35). Media and supplements were purchased from Biological Industries (Bet Ha'emek, Israel).

Cell lines were treated with 600 units/ml alpha /beta interferons (Lee Biomolecular Research Inc., San Diego, CA) for 16 h, or 100 units/ml gamma -interferon (Boehringer, Mannheim, Germany) for 48 h before harvesting.

Stable Transfection

TAP2-transfected Ad12-transformed cells (VAD12.79 Cl1.1, Ref. 34) were transfected by the calcium phosphate-DNA coprecipitation method (34). The transfection mixture contained 10 µg of plasmid DNA (the beta 2m gene expressed from an actin promoter in PBr was constructed in Dr. D. Margulies' laboratory (NIAID, NIH, Bethesda, MD)), 1 µg of plasmid DNA containing the hygromycin gene, and 5 µg of carrier DNA (sheared salmon sperm DNA, Sigma). Twenty-four hours after transfection, the cells were washed with PBS, fresh media was added and after an additional 24 h the medium was supplemented with 110 units/ml hygromycin B (Calbiochem). Following selection of hygromycin-resistant cells, individual cell colonies were isolated and expanded in culture.

Antibodies

The following antibodies were used for immunoprecipitation: 20.8.4S (recognizes the alpha 1/alpha 2 epitope on H-2Kb; Ref. 36); B22.249 (recognizes an alpha 1 epitope on H-2Db; Ref. 36); PT85A (recognizes a public determinant on swine lymphocyte antigens (SLA); Ref. 37). Rabbit antibodies directed against beta 2m were a kind gift from Dr. J. E. Coligan (NIAID, NIH, Bethesda, MD).

Metabolic Labeling and Immunoprecipitation

Cells were grown to 80% confluence and starved for 15 min in methionine-free medium. They were then labeled in methionine-free medium containing 250 mCi/ml [35S]methionine (Amersham International, Little Chalfort, United Kingdom (UK)) for 15 min unless otherwise indicated, washed with PBS, and chased for the indicated intervals. Cells that were labeled for 15 h were incubated in methionine-free medium containing 16% Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 100 mCi/ml [35S]methionine. The cells were lysed with buffer containing 0.5% Triton X-100, 50 mM Tris (pH 7.5), and 150 mM NaCl. The immunoprecipitates were washed with buffer containing 0.1% Triton X-100, 50 mM Tris (pH 7.5), and 150 mM NaCl. For Endo H treatment, immunoprecipitates were eluted by adding 25 µl containing 50 mM Tris (pH 8), 1% SDS, and boiled for 5 min. The samples were centrifuged and the supernatant was added to 25 µl of 50 mM citrate buffer (pH 5.5) containing 500 units of Endo H (New England Biolabs). The samples were incubated at 37 °C for 18 h, followed by the addition of sample buffer. All the buffers contained the following protease inhibitors; 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin (Sigma). The immunoprecipitates were fractionated on 10 or 15% SDS-polyacrylamide gels, and X-Omat AR x-ray films (Eastman Kodak Co.) were exposed to the dried gels.

Preparation of Membranes

Membranes were prepared as described (38). Briefly, cell lysates were separated into two fractions: one containing cell membranes and the other containing soluble proteins. Cell pellets (5 × 107/ml) were resuspended in ice-cold Dounce buffer (10 mM Tris (pH 7.6), 0.5 mM MgCl) with protein inhibitors and incubated on ice for 30 min. The cells were lysed with a Dounce homogenizer, and the tonicity of the solution was restored by adding NaCl to a final concentration of 0.15 M. The suspension was spun at 500 × g to remove the nuclei, and the supernatant was further centrifuged for 45 min at 100,000 × g at 4 °C. The supernatant, which contained soluble proteins, was transferred to a separate tube, and the pellet was resuspended in lysis buffer.

Probes and Plasmids

The following probes have been described previously (32, 33, 34); the actin probe was a PstI-PstI fragment from chicken beta  actin cDNA, the PD1-specific probe was a SacI-BamHI genomic fragment containing exons 2-7 of the PD1 gene, the H-2 probe was an EcoRI-HindIII fragment derived from pH-2d33 (H-2Kd), the beta 2m probe was a PstI-PstI fragment from beta 2m cDNA, and the histone probe was a BamHI genomic fragment. Plasmids containing H-2Kb cDNA and H-2Db genomic (pMo/Db) fragments (40) were used as templates for PCR reactions and were a kind gift from Dr. L. Eisenbach (The Weizmann Institute of Science, Rehovot, Israel) and from Dr. D. Pardoll (Johns Hopkins University, Baltimore, MD), respectively.

Hybridizations

The hybridization solution contained 4 × SSC, 50% formamide, 0.2% SDS, 0.1% polyvinylpyrrolidone, and 100 µg/ml sheared salmon sperm DNA. Hybridizations were carried out at 42 °C, followed by washes with 2 × SSC, 0.1% SDS at room temperature, and 0.2 × SSC at temperatures ranging between 55 and 65 °C. After stripping with a boiling solution of 0.1% SDS, the blots were used for additional hybridizations.

RNA Analysis

Cytoplasmic RNA was prepared using a modification of the White and Bancroft method (41), as described previously (34). RNA was denatured and fractionated on a 1.2% formaldehyde/formamide agarose gel, blotted onto a Hybond-N membrane (Amersham International, Little Chalfort, UK) and hybridized with the appropriate probe, which had been labeled with [alpha -32P]dCTP (Rotem Industries, Dimona, Israel), using a Random Priming labeling kit (U. S. Biochemical Corp.).

Polysome Fractionation

Polysomes were fractionated as described previously (42). Cells were grown to 80% confluence and harvested by trypsinization (0.25 M trypsin EDTA; Biological Industries, Israel). A quantity of 6 × 107 cells was lysed per fractionation. The cells were washed with PBS, and cell pellets were kept at -70 °C until used. Trypsin, PBS, and media contained 100 µg/ml cycloheximide (Sigma). Cells were thawed on ice and suspended in 450 µl of polysomal buffer containing 10 mM NaCl, 10 mM Tris (pH 7.4), 1.5 mM MgCl2, and 50 µl of ribonucleoside vanadyl complexes (200 mM) (New England Biolabs). Cells were lysed following the addition of 60 µl of polysomal buffer containing 10% Triton X-100 and 10% deoxycholate by brief mixing before and after 3 min of incubation on ice. Nuclei were pelleted by centrifugation for 3 min at 4 °C, and the postnuclear supernatant was diluted with an equal volume of 25 mM Tris (pH 7.5), 10 mM MgCl2, 25 mM NaCl, 0.14 M sucrose, 500 µg/ml heparin, 0.05% Triton X-100. The suspension was layered over 35 ml of 15-45% (w/w) sucrose gradient with a 2-ml cushion of 45% sucrose. The sucrose solution contained 25 mM Tris (pH 7.5), 25 ml of NaCl, 2 mM MgCl2. A volume of 36 µl of heparin (from a stock solution of 200 µg/ml) was added to each gradient. The gradients were centrifuged at 26,000 rpm for 4 h at 4 °C in a Beckman SW27 rotor. After centrifugation, 38 fractions of 1 ml each were collected into tubes containing 10 µl of 10% SDS. The A260 was monitored, the polysome profile was determined, and each 2-3 tubes were pooled to give a total of 8-10 tubes. RNA was extracted from polysomal and subpolysomal fractions as described before. Only gradients with identical polysomal profiles were compared.

RT-PCR

Reverse transcription of RNA was carried out for 1 h at 42 °C, in 20 µl of PCR buffer II (Perkin Elmer) containing 1 µg of total cellular RNA, 2.5 µM oligo(dT)18 primer (New England Biolabs), 1 mM nucleotide mixture, 5 mM MgCl2, 35 units of ribonuclease inhibitor (MBI Fermentas, Vilnius, Lithuania), and 7 units of avian myeloblastosis virus reverse trascriptase (Promega, Madison, WI). The cDNA was stored at -20 °C until used.

PCR was carried out with 1 µl of the cDNA, and 50 pmol of the following primers (40): a 5' consensus primer for H-Db and H-2Kb (5'-CGC GAC GCT GCT GCG CAC AG-3'), and 3' primers specific for H-2Db (5'-TAC AAT CTC GGA GAG ACA TT-3') or H-2Kb (5'-TAC AAT CTG GGA GAG ACA GA-3'), 40 µM nucleotide mixture, and 0.375 units of Taq DNA polymerase (Promega). Each PCR cycle included 1 min of denaturation at 94 °C, 1 min of annealing at 65 °C, and 1 min of extension/synthesis at 72 °C. After the appropriate number of PCR cycles (MiniCycler, MJ Research Inc., Watertown, MA), 10 µl or less of the reaction mix were fractionated on a 1% agarose gel. The gel was soaked twice for 20 min in 1.5 M NaCl, 0.5 M NaOH at room temperature and blotted onto a Hybond-N membrane (Amersham International, Little Chalfort, UK) with transfer buffer containing 1.5 M NaCl, 0.25 M NaOH. The membrane was baked for 10 min at 80 °C, and the DNA was cross-linked to the membrane by exposure to UV.

Since both genes yield an RT-PCR product that is identical in size, two positive and two negative controls were included in each set of reactions. A plasmid containing a genomic fragment from H-2Db was amplified with H-2Db primers and with H-2Kb primers, and a plasmid containing H-2Kb cDNA was amplified with H-2Kb primers and with H-2Db primers. Since the yield of the PCR product is proportional to the starting amount of the template, only under conditions in which PCR amplification proceeds exponentially at a constant efficiency (43, 44) is the PCR reaction quantitative. A titration curve for amplified cDNA from each cell line and for each gene was plotted to ensure that the number of amplification cycles was below the plateau level. Detailed analysis of the results is presented under "Results."

Quantitation of Radioactive Signals

Dried radioactive gels or blots were exposed to a phosphoimager screen and analyzed with a phosphoimager (Fuji BAS1000, Tokyo, Japan). The data are presented as phosphostimulated luminescence (PSL) units. In some cases, following scanning densitometric analysis of the x-ray films was performed.


RESULTS

Steady State Level of Class I and beta 2m mRNA in Ad12-transformed Cells

Due to post-transcriptional interference with class I assembly and transport (32, 33), most of the Ad12-transformed cell lines express very low levels of cell surface class I antigens despite having near normal levels of class I mRNA. Fig. 1 (A and B) substantiates previous data from our laboratory (12, 32), demonstrating that nearly all the Ad12-transformed cell lines express normal or elevated levels of the miniature swine class I transgene (PD1) mRNA, and a normal level or less than a 2-fold reduction in H-2 mRNA, as compared with that in the normal cell lines as exemplified by M1. The level of class I mRNA in E1Ad5-transformed cells is either normal or enhanced. Full restoration of cell surface expression level and transport of PD1 was achieved by re-expression of peptide transporter molecules in the Ad12-transformed cell line VAD12.79 (12) but the expression level of H-2Db was only partially restored, and the expression level of H-2Kb remained very low in these TAP-reconstituted and in TAP+LMP-reconstituted cells (12, 34). In order to examine whether the selective suppression of H-2Kb expression was mediated by H-2Kb-specific gene regulatory elements, the mRNA levels of the individual H-2 genes were analyzed in the transformed cells. Since efficient detection and quantitation of H-2 mRNA by Northern blot analysis requires a probe that does not distinguish H-2K from H-2D mRNA, we utilized a quantitative RT-PCR assay in order to determine the relative amounts of mRNA encoded by each of these genes. A total of 5-30 PCR cycles were performed for each of the cDNAs that were reverse-transcribed from total RNA. The PCR products were fractionated on agarose gels, blotted, hybridized to an H-2 probe, and the radioactive signal was quantitated, following various exposure periods. Fig. 2A shows the results of the analyses of H-2 cDNA in one of the transformed cell lines, using specific primers for H-2Kb and H-2Db. The primers were complementary to the same region in the two genes, thus minimizing possible differences that could result from DNA positioning or conformation. Since both sets of primers gave a band of the same size, the specificity of the PCR reaction was proved by the generation of the expected bands, using H-2Kb and H-2Db plasmid DNA templates (Fig. 2B). Analysis of the data showed a linear response curve when the number of PCR cycles ranged between 10 and 25. Similar response curves were obtained for E1Ad5-transformed (A5O1 and A5O5), Ad12-transformed (VAD12.79 and VAD12.42), and the normal cell line M1. Using the linear part of the curves, we compared the mRNA levels for each of the genes in the different cell lines. A representative display of the results is shown in Fig. 2B. The ratios in the levels between H-2Kb and H-2Db were determined, and the values are presented in Table I. These analyses showed that in Ad12-transformed, as well as in the normal and E1Ad5-transformed cell lines the ratio between H-2Kb and H-2Db transcripts is about 1, implying that the level of H-2D and H-2K mRNA is about the same. Thus, in Ad12-transformed cells H-2Kb is not selectively suppressed at the transcriptional level.


Fig. 1.

Steady state level of class I heavy chains and beta 2m in normal and Ad-transformed cell lines. Electrophoresis on a formaldehyde/formamide agarose gel was carried out with 20 µg of total RNA from the "normal" cell line (M1), Ad12-transformed cell lines (VAD12.79, VAD12.42, VAD12.36, VAD12.25, VAD12.20, VAD12.54, and VAD12.43), and Ad5E1-transformed cell lines (A5O1 and A5O5). RNA was transferred to a nylon membrane and hybridized with probes specific for PD1, H-2, beta 2m, and actin (A). The blot was stripped between hybridizations, as indicated under "Experimental Procedures." The results of the normalized densitometric analyses are summarized in B and C. D. U., densitometric units; H. C., heavy chain.


[View Larger Version of this Image (30K GIF file)]



Fig. 2. Comparison of steady state level of H-2Kb and H-2Db mRNA as determined by RT-PCR in normal and Ad-transformed cell lines. RT-PCR was carried out using primers specific for H-2Kb and H-2Db. PCR products were fractionated on agarose gels, blotted onto nylon membranes, and hybridized with an H-2 probe. Each blot was exposed for various time intervals, assuring that of all test points were at the linear detection range of the phosphoimager. A response curve for amplified cDNA from each cell line and for each gene (radioactive signals are presented as log PSL), was plotted as a function of the number of PCR cycles. Representative response curves are shown in A. A representative gel, which includes samples from a normal cell line (M1), E1Ad5-transformed cell line (A5O1 and A5O5) and Ad12-transformed cell lines (VAD12.79 and VAD12.42), is shown in B. The blot was exposed for various intervals, and the results of the best exposure times are displayed. Specificity controls using plasmid DNAs as templates are shown in the first four lanes. The ratio between H-2Db and H-2Kb signals in three individual experiments is summarized in Table I. Db-g, a plasmid containing a genomic fragment of H-2Db. Kb-c, a plasmid containing a cDNA fragment of H-2Kb. RT-PCR prod., RT-PCR products.
[View Larger Version of this Image (35K GIF file)]


Table I.

Relative expression of H-2Db and H-2Kb mRNA in normal and Ad-transformed cells

M1, normal cell line; A5O1 and A5O5, E1Ad5-transformed cell lines; VAD12.79 and VAD12.42, Ad12-transformed cell lines. PSL, phosphostimulated luminescence units.
Exp. Cell line
M1 A5O5 A5O1 VAD12.79 VAD12.42

H-2Db/H-2Kb (PSL)
1 1.2 1.1 0.7 0.8 2.9
2 0.6 0.7 1.7 1.4
3 1.0 1.1

Since a limiting amount of beta 2m could be a factor of major importance in class I assembly and transport, we next determined the levels of beta 2m mRNA in the transformed cells. Fig. 1 (A and C) shows that the steady state levels of beta 2m mRNA varied among the Ad12-transformed cell lines. In VAD12.79 (the cell line that was transfected with TAP and LMP genes and yet demonstrated inefficient transport of H-2 molecules), the beta 2m mRNA level was 2.5-fold lower than that in the normal cell line M1 and 4-fold lower than that in the E1Ad5-transformed cell lines. The reduced levels of beta 2m mRNA in Ad12-transformed cells might limit beta 2m synthesis to a level whereby competition for this molecule by different class I heavy chains results in inefficient assembly and transport of particular class I complexes.

Translation of Class I Heavy Chains and beta 2m mRNA in Ad12-transformed Cells

As we were not able to immunoprecipitate significant amounts of H-2 molecules, even with antibodies directed against the alpha 3 domain or the cytoplasmic tail of class I antigens (33, 34), the possibility that the class I heavy chains and beta 2m transcripts were poorly translated was considered. Polysome-associated RNA from normal and Ad12-transformed cells was fractionated and hybridized with several probes. The control probes were chosen to represent mRNAs of 1.5-kilobase mRNAs (class I heavy chain mRNA was compared with actin mRNA), and of 0.5-kilobase mRNAs (beta 2m mRNA was compared with histone mRNA). Fig. 3 shows a representative experiment in which hybridization signals obtained with polysomal RNA from VAD12.79 and M1 cell lines were compared. The distribution of PD1, H-2, actin, and histone mRNAs was identical in the two cell lines. The maximal level of class I and actin mRNA was in fractions 2-4, and that of histone was in fractions 5 and 6. These results are in agreement with the mRNA sizes of these genes. The distribution of beta 2m mRNA showed a slight shift toward the lighter polysome fraction in VAD12.79 (fractions 3-5 in VAD12.79, compared with fractions 2-4 in M1). While these results were consistent in the VAD12.79 cell line, we did not detect a similar shift in other Ad12-transformed cell lines (data not shown). Therefore we conclude that both class I heavy chains and beta 2m mRNA are efficiently translated in Ad12-transformed cell lines.


Fig. 3. Translation efficiency of class I heavy chains and beta 2m in normal and a Ad12-transformed cell lines. Polysome-associated mRNA was isolated from a normal cell line (M1) and an Ad12-transformed cell line (VAD12.79) and fractionated on a formamide/formaldehyde gel. The gel was blotted and hybridized with PD1-, H-2-, beta 2m-, actin-, and histone-derived probes. L, light; H, heavy.
[View Larger Version of this Image (66K GIF file)]


Overexpression of beta 2m in TAP-reconstituted VAD12.79 Cells Enhances Assembly and Transport of PD1 but Does Not Affect Assembly of H-2 Molecules

Since the intracellular concentration of beta 2m might affect the efficiency of assembly of class I complexes, we attempted to induce assembly and transport by overexpression of beta 2m molecules. TAP-reconstituted VAD12.79 cells were transfected with a vector expressing mouse beta 2m from an actin promoter. Several individual clones that expressed levels of beta 2m identical to the normal cell line were grown, and the transport of PD1 and H-2 molecules was analyzed by immunoprecipitation with antibodies directed against PD1 or against the H-2 heavy chains, respectively. Fig. 4 (A and B) shows two representative pulse-chase experiments performed with two of the transfected clones (clones 2 and 9). The transport rate of PD1 was enhanced in both clones, as evidenced by the rate of acquisition of Endo H resistance especially following the 60-min chase period. This augmentation was not seen with H-2 molecules analyzed in parallel (data not shown). These results were supported by data obtained with TAP-reconstituted Ad12-transformed-cells infected with recombinant vaccinia viruses expressing beta 2m, and with cell extracts to which excess purified human beta 2m was added (data not shown). In all three cases, an excess of beta 2m resulted in augmented assembly and transport of PD1/beta 2m, but did not affect the assembly of H-2/beta 2m. Thus, even in VAD12.79, in which the beta 2m levels are comparable or exceed levels in normal cells, it somehow was not accessible for assembly of H-2 class I complexes.


Fig. 4. Transport of PD1 in beta 2m-transfected TAP-reconstituted VAD12.79 (12.79/TAP2) cells. Transport of PD1 was analyzed in the normal cell line (M1), a mixture of hygromycin-transfected clones (12.79/TAP2 C/Mix), and beta 2m-transfected clones (2 in A and 9 in B), following immunoprecipitation and Endo H treatment. m, mature; imm, immature.
[View Larger Version of this Image (71K GIF file)]


Turnover of beta 2m in Normal and Ad12-transformed Cells

Since increased amounts of newly synthesized beta 2m in the Ad12-transformed cell line did not affect the assembly and transport of H-2 molecules, we next focused on the fate of the beta 2m molecules in these cells. The level and half-life of the assembled and the total beta 2m was assayed in pulse-chase experiments with the relevant antibodies. The level of PD1 in M1 cells is 3-4-fold higher than that of H-2Kb or H-2Db (12), and its maturation rate and half-life resembles that of H-2Kb (33). Consequently, the turnover rate of PD1-associated beta 2m is representation of the mean turnover rate of class I-bound beta 2m in the cells. As can be seen in Fig. 5 (A and B), the half-life of PD1-assembled beta 2m in the normal cell line was greater then 7 h, the half-life of total beta 2m molecules in the normal and in E1Ad5-transformed cell lines was less then 100 min, but in VAD12.79 there was minimal turnover of the beta 2m during this time period. Identical results to that observed in VAD12.79 were obtained with two additional Ad12-transformed cell lines (VAD12.42 and VAD12.36; data not shown). Since the ratio of the heavy chain to the light chain did not change during the chase periods, we feel that the rapid turnover rate of free beta 2m in the normal and in E1Ad5-transformed cell lines represents the true estimation of beta 2m half-life and does not result from an exchange between labeled and non-labeled beta 2m molecules. Thus, our data clearly demonstrate that both assembly of class I/beta 2m (Refs. 12 and 33; see Fig. 7, B1) and secretion or degradation of free beta 2m were both abrogated in Ad12-transformed cells.


Fig. 5. Half-life of beta 2m in normal and Ad-transformed cell lines. A representative pulse-chase experiment demonstrating the turnover of beta 2m in normal (M1), E1Ad5-transformed (A5O5), Ad12-transformed (VAD12.79), TAP1+2- and TAP2-VAD12.79 cells is shown in A. B and C summarize the results of three pulse-chase experiments; cell lysates were immunoprecipitated either with antibodies directed against beta 2m (total beta 2m, B and C), or with antibodies directed against PD1 (PD1-assembled beta 2m, B). The mean ± S.D. of the quantitated signals obtained for beta 2m was calculated as the percent of the signal observed immediately after the 15-min pulse (% of time zero), and is presented as a function of the chase period. Total beta 2m, beta 2m precipitated with antibodies directed against beta 2m. PD1-assembled beta 2m, PD1-associated beta 2m in M1 cells precipitated with antibodies directed against PD1.
[View Larger Version of this Image (27K GIF file)]



Fig. 7. Analysis of soluble and membrane cell fractions for the presence of beta 2m. Cell lysates were prepared following hypotonic shock by Dounce homogenization (A, B1, B2, lanes 1-4), or by 0.1% Triton X-100 solubilization (B2, lanes 5). The lysates were separated into soluble and membrane fractions as described under "Experimental Procedures." Following solubilization of the membranes with 0.1% Triton X-100, both fractions were immunoprecipitated with antibodies against beta 2m (A, B2), or with antibodies against PD1 (B1). In Experiment 2 (B2), the immunoprecipitates were fractionated under reduced or non-reduced conditions, as specified in the figure. Nonspecific bands that immunoprecipitated with anti-PD1 antibodies were observed mainly in the soluble fractions and are marked with an asterisk (B1). The signals were quantitated and are presented as PSL × 10. The specific values of the signals per microgram of protein in the lysates were calculated and are presented in Table II. ME, 2-mercaptoethanol; Fr., fraction.
[View Larger Version of this Image (29K GIF file)]


In order to determine whether poor assembly and the factors retarding beta 2m turnover are related, we determined the half-life of total beta 2m in TAP-reconstituted VAD12.79 cells, which can assemble and transport PD1 molecules (12, 34). Fig. 5 (A and C) shows that in these cells, the half-life of total beta 2m was comparable with that of PD1-assembled beta 2m, and significantly longer than that of total beta 2m in the normal cell line. Pretreatment of Ad12-transformed cells with interferons, which reconstitutes almost completely the assembly and transport of both the PD1 and H-2 molecules (34), enhanced the turnover of beta 2m molecules but did not fully restore their normal turnover rate (Fig. 6, A and B). These results imply that in Ad12-transformed cells there is a mechanism that acts to retain beta 2m in the cells and that this retention is only partially alleviated by reconstituting the assembly of class I complexes.


Fig. 6. Half-life of beta 2m in Ad-12 transformed cell lines following treatment with interferons. A representative pulse-chase experiment demonstrating the turnover of total beta 2m in normal (M1), VAD12.79, and VAD12.79 cells pretreated with alpha /beta or gamma -interferons is shown in A. Panel B summarizes the results of three experiments. The mean ± S.D. of the quantitated signals obtained for beta 2m was calculated as the percent of the signal observed immediately after the 15-min pulse (% of time zero), and is presented as a function of the chase period. Total beta 2m, beta 2m precipitated with antibodies directed against beta 2m.
[View Larger Version of this Image (42K GIF file)]


beta 2m Molecules Are Associated with the Membrane Fraction of Ad12-transformed Cells

In order to localize the compartment where beta 2m is retained in Ad12-transformed cells, we separated cell lysates into two fractions: one enriched for soluble proteins, and the other for cell membranes. The latter fraction was solubilized by detergent treatment, and both fractions were immunoprecipitated with antibodies directed against beta 2m. The results of two experiments are depicted in Fig. 7. In the first (A), the cells were pulsed for 30 min in order to be able to detect molecules with short and long half-lives. In the second (B), the cells were labeled for 15 h to enrich for molecules that have a long half-life. In order to directly determine which fraction was enriched with heavy chain-associated beta 2m molecules, we immunoprecipitated both total (B2) and PD1-assembled beta 2m (B1). The immunoprecipitates were reduced or left untreated before fractionation by polyacrylamide gel electrophoresis. The data were quantitated and are summarized in Table II. The results of both experiments show that the membrane fraction of the two cell lines was enriched for beta 2m. Whereas in M1, beta 2m molecules are associated with class I heavy chains and, therefore, were expected to reside in the membrane fraction, the beta 2m-enriched membrane fraction of VAD12.79 implies that in these cells the beta 2m molecules are associated with another membrane component. Experiment 2 shows that PD1 resides within the membrane fraction of M1 (B1, compare lanes 1 and 3), but, as expected, was absent from extracts of VAD12.79 (B1, lanes 2 and 4). These results confirmed previous data that there was no assembly of heavy chain/beta 2m in VAD12.79 cells and assured us that there was no contamination of the soluble fraction proteins with membrane-bound proteins. The signal obtained for the PD1-associated beta 2m in M1 was comparable with the signal obtained for total beta 2m in the membrane fraction of the same cells (B1, lane 3 compared with B2, lane 3). This result indicates that most of the beta 2m residing in the membrane fraction of M1 cells is bound to class I heavy chains. Unlike M1 in which all membrane-bound beta 2m can be accounted for by class I heavy chain associations, in VAD12.79 some other membrane component must be playing this role. Moreover, the association of this membrane component with beta 2m is more stable than the beta 2m-association with class I heavy chains, as evidenced by the fact that after 15 h of labeling the amount of both soluble (B2, lanes 1 and 2) and membrane beta 2m (B2, lanes 3 and 4), in VAD12.79 cells was 3-fold higher than in the M1 cells, whereas after a short pulse these signals in the membrane fraction were almost identical in both cell lines (A, lanes 3 and 4). The binding between this yet to be identified membrane component and beta 2m is not via covalent disulfide bonds, since the same results were obtained whether or not the immunoprecipitates were reduced before fractionation (Fig. 7).

Table II.

Expression of beta 2m in the soluble and membrane fractions of normal and Ad12-transformed cell lines

M1, normal cell line; VAD12.79, Ad12-transformed cell line; Sol., soluble fraction; Mem., membrane fraction; beta 2m-deg., degraded forms of beta 2m; beta 2m-PD1, beta 2m assembled with PD1; PSL, phospho stimulated luminescence units.
Exp. Cell line M1
VAD12.79
Sol. Mem. Sol. Mem.

PSL/µg protein
1  beta 2m 45 211 95 284
2  beta 2m 91 363 341 1023
 beta 2m-deg. 71 0 0 0
 beta 2m-PD1 0 368 0 0

The fact that VAD12.79 cells appear to posses a unique membrane beta 2m-binding component was further substantiated by the finding that in the soluble fraction of the M1 cells, partial degradation of beta 2m molecules was evident (B2, lanes 1), while no such degradation was detected in the soluble fraction of VAD12.79 cells (B2, lanes 2), despite the fact that the beta 2m signal in these cells was 3.5-fold stronger. Degradation products of beta 2m molecules were also detected in immunoprecipitates of total cell extracts from M1 cells, but not from VAD12.79 cells (B2, lanes 5 and 6, respectively).


DISCUSSION

The selective suppression in transport and cell surface expression of H-2 molecules in Ad12-transformed cells that were reconstituted for the expression of peptide transporter and LMP genes implied that there was an additional factor(s) involved in the assembly and transport of the class I complex. The following possibilities were considered: (a) differences in the steady state level of H-2Kb and H-2Db mRNA, leading to differences in the magnitude of their expression; (b) differences in the translation efficiency of class I transcripts, resulting in differences in the amounts of proteins produced; (c) mutations affecting the conformation of the endogenous class I molecules and, thus preventing their transport through cell organelles; and (d) competition among class I heavy chains for limited amounts of beta 2m or inaccessible beta 2m molecules, leading to selective enrichment in particular class I complexes.

Our data show that equal amounts of H-2Kb and H-2Db genes were transcribed (Fig. 2). We also found that PD1 and H-2 mRNAs were translated efficiently (Fig. 3). In one Ad12-transformed cell line (VAD12.79), we observed some inhibition in the translation of beta 2m mRNA as compared with that in the normal cell line M1. However, even in this cell line, beta 2m mRNA was associated with the polysomal fraction and the slight shift of its mRNA toward association with lighter polysomes was not detected in other Ad12-transformed cell lines. Thus, aberrant transcription or translation of the class I heavy chains or of beta 2m molecules cannot account for the low level of assembled and transported H-2 molecules in the TAP and LMP-reconstituted Ad12-transformed cells.

In order to determine whether inefficient assembly of specific class I heavy chains resulted from mutations in the endogenous genes which affect their conformation, we previously overexpressed either H-2 or beta 2m molecules via infection with recombinant vaccinia viruses and analyzed their assembly and transport (34). The results were comparable with those obtained with the endogenous molecules, i.e. the transport of H-2 molecules was inefficient, while the transport of PD1 was completely restored. In the present study we also found that TAP-reconstituted VAD12.79 cells stably transfected with a beta 2m gene show enhanced assembly and transport of PD1, but not of H-2 molecules (Fig. 4).

Collectively, the data suggested that one of the components (beta 2m or peptides) of the class I complex was not available for assembly and led us to compare in greater detail the fate of beta 2m in the normal versus the transformed cells. Based on our previous immunoprecipitation data and on other studies (45, 46, 47, 48, 49), it seemed likely that in normal cells most of the beta 2m molecules would be associated with class I heavy chains and free molecules would either be degraded or secreted. Several studies have shown that free beta 2m is secreted from cells and that its secretion can be enhanced by various cytokines, growth factors, and growth promoters (47, 48, 49). Dragmont et al. (45) demonstrated that free beta 2m was secreted into the culture media of cell lines independent of cell surface expression of class I heavy chains. beta 2m has also been shown to be secreted from endometrial cells (46), leukemic B cells (47), fibroblasts (48), and hepatocytes (49). Much less is known about the degradation pathway of free beta 2m within the cells. Since in Ad12-transformed cells there is no assembly with class I heavy chains, it seemed likely that most of the beta 2m would be secreted from the cells or rapidly degraded. However, surprisingly, unlike normal and E1Ad5-transformed cells in which free beta 2m was either secreted or degraded, and class I-assembled beta 2m was transported to the cell membrane, in Ad12-transformed cells, free beta 2m was retained in the cells (Fig. 5). Furthermore, we found that most of the beta 2m molecules in the transformed cells resided in the membrane-enriched fraction (Fig. 7) and were more efficiently retained, following an overnight labeling period, than in the normal cell line. These data suggest that in the absence of detectable assembly with class I heavy chains, beta 2m molecules could bind other membrane-associated molecules, resulting in the retention of these molecules within the cell. We cannot completely rule out the possibility of the existence of denatured class I heavy chains in Ad12-transformed cells that have lost all epitopes recognized by the antibodies used for immunoprecipitations and still have the potential to bind beta 2m efficiently and to be retained in a stable form in the ER. Nevertheless, this possibility seems highly unlikely in view of the fact that none of the panel of antibodies directed against epitopes on the alpha 3 domain of H-2Db (33), H-2Dd (34), PD1 (33, 34), and antisera against peptide 8 of the H-2Kb molecules (data not shown) detected significant assembly of the relevant heavy chain with beta 2m.

Since it has been documented that gamma -interferon modulates the secretion of beta 2m (47, 49) and the same cytokine also reconstitutes the transport of H-2 molecules in Ad12-transformed cells (Ref. 34, and data not shown), we pretreated the transformed cells with interferons and determined the half-life of beta 2m. Indeed, interferon treatment significantly shortened the half-life of beta 2m, but it was still longer than in normal or E1Ad5-transformed cells. Thus, we can conclude that in Ad12-transformed cells, most beta 2m is retained in the cells via a membrane-bound component and that it can be partially released by assembly with a class I heavy chain/peptide or by interferon treatment.

beta 2m is known to bind at least two other non-MHC molecules that have low significant homology with class I heavy chains: the neonatal Fc receptor (50, 51) and the CD1 class I-like molecule (51, 52). Neonatal Fc receptors mediate transfer of maternal IgG to the newborn, providing the neonate with humoral immunity before the development of a fully functional immune system. The neonatal Fc receptor shows similarity to the class I heavy chains in the organization of domains and their sequence, especially in the alpha 3 domain (53), a fact that explains its binding to beta 2m molecules. On the other hand, the non-MHC-encoded CD1 family of molecules present antigens entirely distinct from MHC class I, class II, or related molecules (51). The molecules are abundantly expressed on professional antigen-presenting cells and are associated with beta 2m, and their expression and function is independent of the expression of peptide-transporter molecules (52). Thus, it is clear that beta 2m can bind class I-related proteins with apparently diverse functions. It is tempting to speculate that beta 2m can function as a scaffold for multiple proteins and promote their correct folding, as suggested by Solheim et al. (54) for class I heavy chains. In the latter case beta 2m would participate in class I transport not only by stabilization of the class I heavy chains, but also by induction of a heavy chain conformation that enables it to transit to the cell surface. The same group also demonstrated (55) that beta 2m was associated with TAP in a class I negative cell line, supporting the hypothesis that beta 2m can bind to multiple proteins within the cell, either directly or via another molecule(s).

Since beta 2m could function to stabilize and maintain a variety of proteins, the constitutive secretion of beta 2m by a variety of cells may have an important physiological role. Indeed, free beta 2m has been shown to have some unexpected biological activities. beta 2m produced by synovial fibroblasts stimulated by phorbol esters induced collagenase synthesis in these cells (56). beta 2m also increased the number of insulin-like growth factor I transcripts and polypeptides, as well as their receptors, on cultured bone marrow cells (57). These data suggested that beta 2m could be involved in the modulation of connective tissue breakdown and bone remodeling. beta 2m might also play a role in the migration of hematopoietic cell precursors from their site of emergence, the bone marrow, to their site of differentiation, the thymus, since it is produced by a thymic epithelial cell line and is able to induce oriented migration of immature lymphoid bone marrow cells in vitro (58). Cytokines and growth factors that were reported to enhance beta 2m secretion possibly could act via two mechanisms: enhancement of beta 2m transcription and induction of beta 2m release from specific cellular proteins that might be similar to the beta 2m-binding proteins described in this paper.

Another system that is similar in several aspects to that described above is the association of surrogate immunoglobulin light chains with glycoproteins in cells that do not express the immunoglobulin heavy chain (59). The complex of µ heavy chain/surrogate light chain is expressed on pre-B cell lines and has been found to transmit biochemical signals to the cells (60, 61). However, the surrogate light chain can be expressed on the cell surface in the absence of rearranged heavy chain. Several proteins were suggested as potential candidates for binding non-covalently the surrogate light chain and carrying it to the surface of pre-B and pro-B cell lines (59). Unlike the surrogate light chains, some classical immunoglobulin light chains, in the absence of heavy chains, are retained and degraded within the ER (62). The half-life of these molecules depends on their binding and dissociation from the chaperone BiP. Our data suggest that, like the surrogate light chains, beta 2m molecules can bind other molecules in the absence of efficient assembly with class I heavy chains. However, such molecules either have long half-life (>5 h) and/or they are not transported to the cell surface and remain associated with beta 2m molecules in the cells. Whether these beta 2m-binding molecules are expressed in normal cells, or are known chaperons such as BiP or calnexin that bind misfolded proteins, or are novel proteins, which are overexpressed in Ad12-transformed cells, remains to be determined. The fact that in Ad12-transformed cells the membrane fraction is enriched with beta 2m suggests that at least one binding protein is a membrane-bound protein such as calnexin. However, calnexin is commonly thought to be a chaperone that binds mostly glycoproteins (63), although a different mechanism for its association with class I heavy chains and class II invariant chains has been suggested (64, 65). Both of these molecules associated with calnexin even when their glycosylation was inhibited, and in the latter case, calnexin association retained the invariant chain in the ER and prevented its degradation. Thus, it is conceivable that beta 2m binds calnexin or another molecule via a mechanism similar to that involved in class II invariant chain association.

If Ad12-transformed cells overexpress a beta 2m-binding protein, it might interfere with the assembly of class I heavy chain/beta 2m/peptide. The ability of this protein to successfully compete with class I heavy chains for beta 2m binding could explain our inability to fully restore the assembly of the H-2 complex in TAP+LMP-reconstituted cells. Thus, Ad12-transformed cells appear to acquire a novel membrane-associated mechanism for sequestering beta 2m. This mechanism may be unique to these cells or may be induced in cells that do not express fully conformed class I complexes.


FOOTNOTES

*   This work was supported by the US-Israel Binational Science Fund, by a grant from the Israel Health Ministry, and by the Israel Association Against Cancer Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed. Tel.: 972-3-6409238; Fax: 972-3-6422046; E-mail: rachele{at}ccsg.tau.ac.il.
1    The abbreviations used are: MHC, major histocompatibility complex; TAP, transporter associated with antigen presentation; ER, endoplasmic reticulum; PBS, phosphate-buffered saline; Endo H, endoglycosidase H; PCR, polymerase chain reaction; RT-PCR, reverse transcription-PCR; PSL, phosphostimulated luminescence; LMP, low molecular mass protein.

Acknowledgment

We are grateful to Dr. John E. Coligan (NIAID, National Institutes of Health) for the critical reviewing of the manuscript.


REFERENCES

  1. Zinkernagel, R., and Doherty, P. C. (1979) Adv. Immunol. 22, 51-177
  2. Goodenow, R. S., Vogel, J. M., and Linsk, R. L. (1985) Science 230, 777-783 [Medline] [Order article via Infotrieve]
  3. Hämmerling, G. J., Klar, D., Pulm, W., Momburg, F., and Moldenhauer, G. (1987) Biochim. Biophys. Acta 179, 245-259
  4. Ehrlich, R. (1995) Immunol. Res. 14, 77-97 [Medline] [Order article via Infotrieve]
  5. Yewdell, J. W., and Bennink, J. R. (1992) Adv. Immunol. 52, 1-123 [Medline] [Order article via Infotrieve]
  6. Germain, R. N., and Margulies, D. H. (1993) Annu. Rev. Immunol. 11, 403-450 [CrossRef][Medline] [Order article via Infotrieve]
  7. Spies, T., and DeMars, R. (1991) Nature 351, 323-324 [CrossRef][Medline] [Order article via Infotrieve]
  8. Attaya, M., Jameson, S., Martinez, C. K., Hermel, E., Aldrich, C., Forman, J., Fischer Lindahl, K., Bevan, M. J., and Monaco, J. J. (1992) Nature 355, 647-649 [CrossRef][Medline] [Order article via Infotrieve]
  9. Van Kaer, L., Ashton-Rickardt, P. G., Ploegh, H. L., and Tonegawa, S. (1992) Cell 71, 1205-1214 [Medline] [Order article via Infotrieve]
  10. Arnold, D., Driscoll, J., Androlewicz, M., Hughes, E., Creswell, P., and Spies, T. (1992) Nature 360, 171-174 [CrossRef][Medline] [Order article via Infotrieve]
  11. Restifo, N. P., Esquivel, F., Kawakami, Y., Yewdell, J. W., Mule, J. J., Rosenberg, S. A., and Bennink, J. (1993) J. Exp. Med. 177, 265-272 [Abstract]
  12. Rotem-Yehudar, R., Winograd, S., Sela, S., Coligan, J. E., and Ehrlich, R. (1994) J. Exp. Med. 180, 477-488 [Abstract]
  13. Williams, D. B., Barber, B. H., Flavell, R. A., and Allen, H. (1989) J. Immunol. 142, 2796-2806 [Abstract/Free Full Text]
  14. Zijlstra, M., Bix, M., Simister, N. E., Loring, J. M., Raulet, D. H., and Jaenisch, R. (1990) Nature 344, 742-746 [CrossRef][Medline] [Order article via Infotrieve]
  15. Koller, B. H., Marrack, P., Kappler, J. W., and Smithies, O. (1990) Science 248, 1227-1230 [Medline] [Order article via Infotrieve]
  16. Rock, K. L., Rothstein, L. E., Gamble, S. R., and Benacerraf, B. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7517-7521 [Abstract]
  17. Vitiello, A., Potter, T. A., and Sherman, L. A. (1990) Science 250, 1423-1426 [Medline] [Order article via Infotrieve]
  18. Rock, K. L., Gamble, S., Rothstein, L., and Benacerraf, B (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 301-304 [Abstract]
  19. Kozlowski, S., Takeshita, T., Boehncke, W.-H., Takahashi, H., Boyd, L. F., Germain, R. N., Berzofsky, J. A., and Margulies, D. H. (1991) Nature 349, 74-77 [CrossRef][Medline] [Order article via Infotrieve]
  20. Boyde, L. F., Kozlowski, S., and Margulies, D. H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2242-2250 [Abstract]
  21. Otten, G. R., Bikoff, E., Ribaudo, R. K., Kozlowski, S., Margulies, D. H., and Germain, R. (1992) J. Immunol. 148, 3723-3732 [Abstract/Free Full Text]
  22. Abdel Motal, U., Zhou, M., X., Siddiqi, A. R., and Jondal, M. (1993) Scand. J. Immunol. 38, 395-400 [Medline] [Order article via Infotrieve]
  23. Rock, k. L., Gamble, S., Rothstein, L., Gramm, C., and Benacerraf, B. (1991) Cell 65, 611-620 [CrossRef][Medline] [Order article via Infotrieve]
  24. Manicourt, D., Brauman, H., and Orloff, S. (1978) Ann. Rheum. Dis. 37, 328-332 [Abstract]
  25. Maury, C. P. J., Helve, T., and Sjoblom, C. (1982) Rheumatol. Int. 2, 145-149 [Medline] [Order article via Infotrieve]
  26. Child, J. A., Spati, B., and Illingworth, S. (1980) Cancer 45, 318-326 [Medline] [Order article via Infotrieve]
  27. Goldman, M. H., Landwehr, D. M., and Lippman, R. (1982) Transplant. Proc. 14, 437-439 [Medline] [Order article via Infotrieve]
  28. Beorcia, S., Vincent, C., and Revillard, J. P. (1981) Clin. Chim. Acta 109, 245-255 [Medline] [Order article via Infotrieve]
  29. Hoffmann, B., Baas, H., Nishanian, P., Faisal, M., Figlin, R. A., Sarna, G. P., and Fahey, J. L. (1992) Clin. Exp. Immunol. 88, 548-554 [Medline] [Order article via Infotrieve]
  30. Homma, T., Tsujinaka, T., Kido, Y., Yasuda, T., Murata, A., and Mori, T. (1992) Eur. Surg. Res. 24, 204-210 [Medline] [Order article via Infotrieve]
  31. Rock, K. L., Fleischacker, C., and Gamble, S. (1993) J. Immunol. 150, 1244-1252 [Abstract/Free Full Text]
  32. Shemesh, J., Rotem-Yehudar, R., and Ehrlich, R. (1991) J. Virol. 65, 5544-5548 [Medline] [Order article via Infotrieve]
  33. Shemesh, J., and Ehrlich, R. (1993) J. Biol. Chem. 268, 15704-15711 [Abstract/Free Full Text]
  34. Rotem-Yehudar, R., Groettrup, M., Soza, A., Kloetzel, P.-M., and Ehrlich, R. (1996) J. Exp. Med. 183, 499-514 [Abstract]
  35. Jacoby, W. B., and Pastan, I. H. (1979) Methods Enzymol. 58, 110-116 [Medline] [Order article via Infotrieve]
  36. Ozato, K., and Sachs, D. H. (1981) J. Immunol. 126, 317-321 [Abstract/Free Full Text]
  37. Davis, W. C., Marusic, S., Lewin, H. A., Splitter, G. A., Perryman, L. E., McGuire, T. C., and Gorham, J. R. (1987) Vet. Immunol. Immunopathol. 15, 337-376 [CrossRef][Medline] [Order article via Infotrieve]
  38. Current Protocols in Immunology, pp. 81.2-8.1.5, John Wiley & Sons, New YorkColigan, J. E., Kruisbeek, A. M., Margulies, D., Shevach, E. M., and Strober, W. (eds). (1994) Current Protocols in Immunology, pp. 81.2-8.1.5, John Wiley & Sons, New York
  39. Cleveland, D. W., Lopata, M. A., MacDonald, R. J., Cowan, N. J., Rutter, W. J., and Kirschner, M. W. (1980) Cell 20, 95-105 [Medline] [Order article via Infotrieve]
  40. Levitsky, H. I., Lazenby, A., Hayashi, R. J., and Pardoll, D. M. (1994) J. Exp. Med. 179, 1215-1224 [Abstract]
  41. White, B. A., and Bancroft, F. C. (1982) J. Biol. Chem. 257, 8569-8572 [Abstract/Free Full Text]
  42. Meyuhas, O., Thompson, E. A., Jr., and Perry, R. (1987) Mol. Cell. Biol. 7, 2691-2699 [Medline] [Order article via Infotrieve]
  43. Moonan, K. E., Beck, C., Holzmayer, T. A., Chin, J. E., Wunder, J. S., Andruilis, I. L., Gazdar, A. F., Willman, C. L., Griffin, B., Von Hoff, D. D., and Robinson, I. B. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7160-7164 [Abstract]
  44. Chelly, J., Kaplan, J.-C., Maire, P., Gautron, S., and Kahn, A. (1988) Nature 333, 858-860 [CrossRef][Medline] [Order article via Infotrieve]
  45. Dargemont, C., Dunon, D., Salamero, J., Deugnier, M. A., Davoust, J., and Thierry, J. P. (1991) J. Cell. Sci. 98, 559-565 [Abstract]
  46. Vallet, J. L., Barker, P. J, Lamming, G. E., Skinner, N., and Huskisson, N. S. (1991) J. Endocrinol. 130, R1-4 [Abstract]
  47. Jones, R. A., Drexler, H. G., Gignac, S. M., Child, J. A., and Scott, C. S. (1990) Br. J. Cancer 61, 675-680 [Medline] [Order article via Infotrieve]
  48. Golds, E. E., Mason, P., and Nyirkos, P. (1989) Biochem. J. 15, 585-588
  49. Ramadory, G., Mitch, A., Rieder, H., and Meyer-zum-Buschenfelde, K. H. (1988) Eur. J. Clinic. Invest 18, 343-351 [Medline] [Order article via Infotrieve]
  50. Israel, E. J., Patel, V. K., Taylor, S. F., Marshak-Rothstein, A., and Simister, N. E. (1995) J. Immunol. 154, 6246-6251 [Abstract/Free Full Text]
  51. Beckman, E. M., and Brenner, M. B. (1995) Immunology Today 16, 349-352 [CrossRef][Medline] [Order article via Infotrieve]
  52. Brutkicwicz, R. R., Bennink, J. R., Yewdell, J. W., and Bendelac, A. (1995) J. Exp. Med. 182, 1913-1919 [Abstract]
  53. Burmeister, W. P., Gastinel, L. N., Simister, N. E., Blum, M. L., and Bjorkman, P. J. (1994) Nature 372, 336-343 [CrossRef][Medline] [Order article via Infotrieve]
  54. Solheim, J. C., Johnson, N. A., Carreno, B. M., Lie, W. R., and Hansen, T. H. (1995) Eur. J. Immunol. 25, 3011-3016 [Medline] [Order article via Infotrieve]
  55. Carreno, B. M., Solheim, J. C., Harris, M., Stronowski, I., Connoly, J. M., and Hansen, T. H. (1995) J. Immunol. 155, 4726-4733 [Abstract]
  56. Brinckerhoff, C. E., Mitchell, T. I., Karmilowicz, M. J., Kluve-Beckerman, B., and Benson, M. D. (1989) Science 243, 655-657 [Medline] [Order article via Infotrieve]
  57. Centrella, M., McCarthy, T. L., and Canalis, E. (1989) J. Biol. Chem. 264, 18268-18271 [Abstract/Free Full Text]
  58. Dargemont, C., Dunon, D., Deugnier, M.-A., Denoyelle, M., Girault, J.-M., Lederer, F., Le, K. H. D., Godeau, F., Thierry, J. P., and Imhof, B. A. (1989) Science 246, 803-806 [Medline] [Order article via Infotrieve]
  59. Karasuyama, H., Rolink, A., and Melchers, F. (1993) J. Exp. Med. 178, 469-478 [Abstract]
  60. Misner, V., Downey, G. P., and Jongstra, J. (1991) Int. Immunol. 3, 1129-1136 [Abstract]
  61. Takemori, T., Mizuguchi, J., Miazoe, I., Nakanishi, M., Shigemoto, K., kimoto, H., Shirasawa, T., Naruyama, N., and Taniguchi, M. (1990) EMBO J. 9, 2493-2500 [Abstract]
  62. Knittler, M. R., Dirks, S., and Haas, I. G. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1764-1768 [Abstract]
  63. Hammond, C., Braakman, I., and Helenius, A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 913-917 [Abstract]
  64. Carreno, B. M., Schreiber, K. L., McKean, D. J., Stronowski, I., and Hansen, T. H. (1995) J. Immunol. 54, 5173-5180
  65. Romagnoli, P., and Germain, R. N. (1995) J. Exp. Med. 182, 2027-2036 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.